UNSPSC 51111856: Lapatinib

This classification denotes an epidermal growth factor receptor tyrosine kinase inhibitor with the molecular formula C29H26CLFN4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0VUA21238F. European Medicines Agency schedules lapatinib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25379. The term LAPATINIB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, no. 1, 2004, list 51). Most nations schedule lapatinib under HS 29349990 and SITC 51579.

As of Q4 2014, LAPATINIB remains the US FDA Preferred Term for this commodity. Lapatinib bears US NLM identifiers UMLS ID C1506770 and NCI Concept Code C26653. SMILES: CLC1CC(NC2NCNC3C2CC(C2OC(CNCCS(=O)(=O)C)CC2)CC3)CCC1OCC1CC(F)CCC1.

UNSPSC 51111856 Lapatinib is a Commodity code identifying a specific targeted cancer therapeutic drug. State and local governments procure lapatinib primarily through Medicaid pharmacy programs, corrections health services, and public health agencies that serve uninsured or underinsured populations. The code reflects lapatinib's role as a tyrosine kinase inhibitor used in the treatment of certain HER2-positive breast cancers and gastric cancers, procured as a line-item pharmaceutical within formulary management and bulk purchasing agreements. Issuing bodies include state Medicaid agencies, departments of health and human services, county health departments, and state prison health systems, which negotiate pricing and supply through group purchasing organizations, prime vendor agreements, and state pharmaceutical contracts. The work involves establishing supply relationships, managing inventory turnover, and negotiating rebates and volume discounts rather than manufacturing or clinical trial activity.

The source material provided contains no recent state or local contract opportunities or active solicitations under this code and does not identify geographic concentration or issuing-body activity patterns. Without access to current RFP, RFQ, IFB, or ITB postings from state procurement portals or county health agencies, no representative recent opportunities can be named.